&lt;p&gt;Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy&lt;/p&gt;

Zhao, Yue; Wang, Xiaolei; Huang, Yuanxi; Zhou, Xian‐Li; Zhang, Dongwei

doi:10.2147/cmar.s198844

Cited by 6 publications

(4 citation statements)

References 31 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study in Ki67, Prihantono et al In 2017 found that Ki67 had a strong positive correlation with neoadjuvant chemotherapy response, while Zhao et al found that Ki67 and HER2 could significantly predict disease free survival (DSF) and ER, PR, HER2-neu, Ki67 can predicted overall survival (OS). 21 In contrast to the results in this study, Ki67 did not have a significant relationship with response to neoadjuvant chemotherapy.…”

Section: Discussioncontrasting

confidence: 99%

Accuracy of a Novel Scoring System for Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

Qodir

Utami

Bahar

2021

sjs

View full text Add to dashboard Cite

Background: Neoadjuvant chemotherapy (NAC) has become a widely accepted treatment option for locally advanced breast cancer (LABC). Furthermore, response to NAC is considered to be a predictor of favorable outcomes. It is known that some predictors are associated with NAC response. Objectives: To assess the accuracy of scoring system for prediction of response to neoadjuvant chemotherapy in LABC. Methods: Medical record of 50 patients received NAC at Mohammad Hoesin Hospital were retrospectively analysed between July 2019 to July 2020. Response of NAC in LABC was determined with Response Evaluation Criteria in Solid Tumours (RECIST). Variables of the scoring system are risk factors of breast cancer, immunohistochemical subtype, CD4+, CD8+, CD4+/CD8+ ratio, and neutrophil to lymphocyte ratio. Results: A total of 50 patients with LABC received and completed NAC. The mean age was 48.2 ± 11.0 at the time of diagnosis. Good response to NAC was achieved in 38 patients (76.0%). This scoring system shows a sensitivity of 77.8%, a specificity of 83.3%, a positive predictive value of 18.4%, and a negative predictive value of 24.4% with the Youden index of 66.1. The combination between less than three parity and positive estrogen receptor demonstrated better accuracy with a sensitivity of 96.3% and specificity of 77.7% and Youden index 74. Conclusion: This pilot study suggests that this scoring system is potentially useful for predicting response to neoadjuvant chemotherapy in LABC patients and warrants further investigation in a larger population to validate this finding.

show abstract

Section: Discussioncontrasting

confidence: 99%

Accuracy of a Novel Scoring System for Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

Qodir

Utami

Bahar

2021

sjs

View full text Add to dashboard Cite

show abstract

“…Previous studies have indicated that the IHC markers of BC patients show varying degrees of alterations after NAC. [ 38 , 39 ] In the present study, among the 91 non-pCR patients, the conversion rates of ER and HER2 were 4.4% and 6.6%, respectively. The conversion rate of PR was 22%, higher than ER and HER2, mainly changed in luminal B patients.…”

Section: Discussionsupporting

confidence: 43%

HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer

Fang,

Zhang,

et al. 2024

Medicine

View full text Add to dashboard Cite

The growing body of evidence suggests that breast cancer (BC) who achieve pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) may experience a more favorable prognosis. The objective of this study is to investigate the correlation between clinicopathologic parameters of locally advanced breast cancer (LABC) patients and the outcomes of NAC, with the aim of identifying predictive indicators for pCR. Additionally, we seek to examine the conversion of IHC markers in pCR patients following NAC and its impact on the prognosis of BC patients. We conducted a study involving 126 patients with LABC. Clinicopathological parameters associated with pCR were subjected to univariate and multivariate analysis. Kaplan–Meier (KM) curves and the log-rank test were used to compare the statistical difference in prognosis in different groups of patients. Additionally, we used difference and consistency tests to examine the conversion of immunohistochemistry (IHC) markers following NAC. The status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and molecular subtypes of BC were associated with pCR in the univariate analysis (all P < .05), which may be potential markers to predict pCR. HER2 was identified as an independent factor for predicting pCR in the multivariate analysis. The pCR rate of HER2-positive patients who received NAC combined targeted therapy was higher than that of patients who only received NAC (P = .003). The disease-free survival (DFS) rate of TNBC patients who achieved pCR was significantly higher than that of non-pCR TNBC patients (P = .026). The IHC marker conversion after NAC mainly existed in PR (P = .041). Ki67 expression decreased in the luminal B subtype and increased in the HER2 enriched subtype after NAC (all P < .001). Patients with Ki67 expression change after NAC had longer overall survival (OS) and DFS than unchanged patients (all P < .05). HER2-positive is an independent indicator for predicting pCR, and HE2-positive patients who received NAC combined targeted therapy were favorable to achieving pCR. IHC markers of BC patients exhibit varying degrees of alterations after NAC, and changes in Ki67 expression after NAC could serve as a marker to predict a better prognosis.

show abstract

“…We also concluded that HER-2 expression was an independent predictor of pCR(P < 0.001). HER2-positive cancers are more aggressive than HER2-negative but better for chemotherapy and endocrine therapy to achieve pCR 39 . The application of trastuzumab is also becoming increasingly popular, and the prognosis of YWBC has improved.…”

Section: Discussionmentioning

confidence: 99%

Comparison of clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in women under 35 years and older women with breast cancer

Dou,

Gao,

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Age has been confirmed to be a very aggressive biological factor associated with the poor prognosis of breast cancer (BC) patients. But the understanding of young women's breast cancer (YWBC) is scarce. This study compares and evaluates the clinical characteristics and pCR rate after neoadjuvant chemotherapy (NAC) in YWBC and older women with BC. Patients and methods We retrospectively analyzed the clinicopathological data, molecular subtypes, chemotherapy regimen, and pCR rates of 1419 non-metastatic BC patients from the Affiliated Cancer Hospital of Harbin Medical University from January 1, 2012, to December 31, 2019. Patients were classified according to age (35 years old and below vs above 35 years old) with the clinical parameters. Categorical data were compared using the chi-square test and Fisher's exact test for multivariate data using Logistic regression models. Any predictor variable with P < 0.05 in the univariate analysis was included in the multivariate regression analysis to study the relationship between different age groups and pCR. Results A total of 879 patients in this study were eligible for analysis, and 71(8.1%) female patients were ≤ 35 years old. YWBC were more likely to get pCR (25.4%vs15.6%, P = 0.033). The proportion of patients with a higher clinical stage was higher. Compared with elderly patients, YWBC patients were more likely to undergo breast-conserving surgery (BCS), multivariate analyses found similar results in different age groups, and more patients with HER-2 positive and triple-negative breast cancer (TNBC). In the whole group, Age, PR expression, HER-2 expression, KI67 expression, and clinical stage were the independent predictors of pCR after NAC in BC patients (P < 0.05). Conclusion Our study found that age is the main factor affecting the achievement of pCR in patients with BC. YWBC has a higher clinical stage and a high proportion of HER-2 positive patients, which is the leading cause of poor prognosis. YWBC has a higher effect on chemotherapy. We need to pay more attention to this group and achieve individualized treatment, which will help us treat BC better and provide new targets and blueprints for our clinical therapy.

show abstract

<p>Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy</p>

Cited by 6 publications

References 31 publications

Accuracy of a Novel Scoring System for Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

Accuracy of a Novel Scoring System for Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer

Comparison of clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in women under 35 years and older women with breast cancer

Contact Info

Product

Resources

About